Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

AnaptysBio, Inc. - Common Stock (NQ:ANAB)

47.89 -1.31 (-2.66%)
Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AnaptysBio, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
AnaptysBio Announces Stock Repurchase Plan
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process. 
Via Benzinga
News headline image
HC Wainwright Sees 40% Upside For This Once Battered Stock With Pipeline Turnaround ↗
 
Via Benzinga
News headline image
AnaptysBio Sells Royalty Interest In Cancer Drug For $45M ↗
 
Via Benzinga
News headline image
Raymond James Initiates AnaptysBio With ~42% Upside, Despite Trial Setback ↗
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session ↗
 
Via Benzinga
News headline image
Greenbrier, Fate Therapeutics, AnaptysBio And Some Other Big Stocks Moving Lower On Friday ↗
U.S. stocks traded higher, with the Dow Jones gaining more than 500 points on Friday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session ↗
 
Via Benzinga
News headline image
AnaptysBio Announces Portfolio Update Across Best-in-Class Immune Cell Modulating Antibodies
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Short Volatility Alert: AnaptysBio, Inc. ↗
On Wednesday, shares of AnaptysBio, Inc. (NASDAQ: ANAB) experienced volatile short activity. After the activity, the stock price went down -3.95% to $19.19. The overall sentiment... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For January 6, 2023 ↗
 
Via Benzinga
News headline image
AnaptysBio- and GSK-partnered immuno-oncology agent JEMPERLI (dostarlimab-gxly) meets primary endpoint in Phase 3 RUBY trial in primary advanced or recurrent endometrial cancer
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio to Participate at the Piper Sandler 34th Annual Healthcare Conference
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Expert Ratings for AnaptysBio ↗
Over the past 3 months, 4 analysts have published their opinion on AnaptysBio (NASDAQ:ANAB) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a... 
Via Benzinga
News headline image
AnaptysBio to Participate in Upcoming November Investor Conferences
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
AnaptysBio Announces Third Quarter 2022 Financial Results and Provides Pipeline Update
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
AnaptysBio / GSK-Partnered Immuno-Oncology Agent Meets Primary Goal In Lung Cancer Trial ↗
 
Via Benzinga
News headline image
AnaptysBio and GSK-partnered immuno-oncology agents JEMPERLI (dostarlimab-gxly) and cobolimab show positive progress in two separate non-small cell lung cancer trials
From AnaptysBio, Inc.
Via GlobeNewswire
News headline image
This Analyst Slashes PT On Rent the Runway By Around 43%, Plus JP Morgan Predicts $84 For Oracle ↗
Credit Suisse cut the price target for Rent the Runway, Inc. (NASDAQ: RENT) from $7 to $4. Rent the Runway shares fell 30.6% to trade at $3.42 on Tuesday. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 13, 2022 ↗
Upgrades See all analyst ratings upgrades. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 1, 2022 ↗
Upgrades 
Via Benzinga
News headline image
AnaptysBio Faces Another Setback For Imsidolimab, Stalls Work In Skin Scarring Indication ↗
AnaptysBio Inc (NASDAQ: ANAB) announced topline data from its HARP Phase 2 trial of imsidolimab for moderate-to-severe hidradenitis suppurativa (HS).  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
During Friday's session, 59 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Thursday ↗
During the Thursday's session, 100 stocks hit new 52-week lows. 
Via Benzinga
News headline image
AnaptysBio's Return On Capital Employed Insights ↗
Benzinga Pro data, AnaptysBio (NASDAQ:ANAB) reported Q1 sales of $970.00 thousand. Earnings fell to a loss of $36.26 million, resulting in a 11.42% decrease from last quarter. 
Via Benzinga
News headline image
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.